Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07142954RecruitingPhase 3
Alzheimer's research study for healthy people
This study is looking at healthy people with no memory concerns to better understand early signs of Alzheimer's disease. You would provide samples and do thinking tests, but you won't take any experimental medicines.
Houston, TexasAges 55–75 - NCT07031687Recruiting
A new brain stimulation study for early Alzheimer's
This study tests a non-invasive brain stimulation method (temporal interference stimulation) to see if it can improve memory in people with early signs of Alzheimer's disease. It aims to understand how the stimulation affects brain function.
Sanya, HainanAges 60–80 - NCT06793735Recruiting
Virtual reality app for memory and thinking problems
This trial tests a virtual reality app you can use at home to help with early memory or thinking problems. It may be an option if you have mild cognitive impairment or notice your thinking is slowing down.
Messina, ItalyAges 40–80 - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06585384RecruitingPhase 1
Safety of etanercept with contrast ultrasound for Alzheimer's
This study tests whether combining a drug called etanercept with repeated contrast ultrasound is safe for people with mild Alzheimer's. It aims to see if this approach can help slow the disease.
ParisAges 50–85 - NCT06582706RecruitingPhase 1/Phase 2
Vitamin B3 (niacin) for Alzheimer's disease
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Indianapolis, IndianaAges 60–85 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06523296Recruiting
Antibodies and thinking problems in myasthenia or Alzheimer's
This study looks at whether certain antibodies are linked to memory and thinking problems in people with myasthenia gravis or Alzheimer's disease. It involves a one-time use of leftover spinal fluid from a previous diagnostic test.
Nice, Alpes MaritimesAges 18 years+ - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT05477862Enrolling by invitation
Improvised music for Alzheimer's anxiety
This study looks at how creating music in the moment (improvisation) affects anxiety and brain function in people with mild to moderate Alzheimer's disease. It may help reduce agitation and improve quality of life.
Chicago, IllinoisAges 55–100 - NCT05295615Recruiting
Pulsed magnetic treatment for mild to moderate Alzheimer’s
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
Hackensack, New JerseyAges 50–100 - NCT03810794Recruiting
Acupuncture study for people with Alzheimer’s memory problems
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
Shanghai, Shanghai MunicipalityAges 50–85 - NCT04902703RecruitingPhase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Aurora, ColoradoAges 60–85 - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT02414347Recruiting
Tau PET scan study for Alzheimer’s disease
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
St Louis, MissouriAges 18 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT07764146RecruitingPhase 1
Study of VY1706 for early Alzheimer's disease
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
Maitland, FloridaAges 30–80 - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Irvine, CaliforniaAges 55–80
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 305 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.